Global Ivermectin Market
Global Ivermectin Market

Ivermectin Comprehensive Study by Application (Hospitals, Clinics, Research Centre), Form (Oral Tablet, Cream, Lotion), End User (Aged 18-65 Years, Aged 0-17 Years, Aged 65 and Above) Players and Region - Global Market Outlook to 2025

Ivermectin Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

May 2020 Edition 244 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Ivermectin Market Definition
Ivermectin is an anthelmintic medication which is a prescription drug used to treat many types of parasite infections available in different forms like oral tablets, cream, and lotion under different brand names Stromectol, Soolantra. Ivermectin treat the skin infections called strongyloidiasis, it is also used to control onchocerciasis helping improve quality of life, people with weak immune system curing the infections can reduce the risk of developing a life-threatening infection. Currently, Ivermectin is being researched on the treatment for virus SARS-CoV-2 that causes COVID-19.

The market study is broken down, by Application (Hospitals, Clinics and Research Centre) and major geographies with country level splits.

Merck & Co., Inc. (United States), Perrigo Company plc (Ireland), Galderma Laboratories LP (United States), MedinCell S.A (France), Hebei Veyong Animal Pharmaceutical Co., Ltd., (China), Hovione Farmaciencia (Portugal), Shandong Qilu King-Phar Pharmaceutical Co., Ltd. (China) and Zydus Cadila (India) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Ivermectin market by Type, Application and Region.

On the basis of geography, the market of Ivermectin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Oral Tablet will boost the Ivermectin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Aged 18-65 Years will boost the Ivermectin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

On 6th April 2020, MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin. and First in-vitro validation of the impact of Ivermectin on Covid-19 by Australian researchers. Future clinical studies will have to confirm the action of Ivermectin on the Covid-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission.
"Ivermectin tablets are approved for use in humans for the treatment of some parasitic worms (intestinal strongyloidiasis and onchocerciasis) and ivermectin topical formulations are approved for human use by prescription only for the treatment of external parasites such as headlice and for skin conditions such as rosacea. Ivermectin is FDA-approved for use in animals for the prevention of heartworm disease in some small animal species, and for the treatment of certain internal and external parasites in various animal species. People should never take animal drugs, as the FDA has only evaluated their safety and effectiveness in the particular species for which they are labeled. Using these products in humans could cause serious harm."

Market Trend
  • Continuous Research and Development on Ivermectin for Drug Discovery for Severe Diseases

Market Drivers
  • Increasing Prevalence of Parasitic Infections on Skin
  • Demand for Parasitic Drug for Animals

Opportunities
  • Increased Spending on Pharmaceutical Industry
  • Clinical Trials on Ivermectin for Drug Testing

Restraints
  • Side Effects Associated with Consumption of Ivermectin

Challenges
  • Stringent Regulatory Standards on Ivermectin
  • Less Awareness about the Skin Related Problems and its Treatment


Key Target Audience
Ivermectin Manufacturers, Ivermectin International Traders, Ivermectin Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Clinics
  • Research Centre
By Form
  • Oral Tablet
  • Cream
  • Lotion

By End User
  • Aged 18-65 Years
  • Aged 0-17 Years
  • Aged 65 and Above

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Parasitic Infections on Skin
      • 3.2.2. Demand for Parasitic Drug for Animals
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Standards on Ivermectin
      • 3.3.2. Less Awareness about the Skin Related Problems and its Treatment
    • 3.4. Market Trends
      • 3.4.1. Continuous Research and Development on Ivermectin for Drug Discovery for Severe Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ivermectin, by Application, Form, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Ivermectin (Value)
      • 5.2.1. Global Ivermectin by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Research Centre
      • 5.2.2. Global Ivermectin by: Form (Value)
        • 5.2.2.1. Oral Tablet
        • 5.2.2.2. Cream
        • 5.2.2.3. Lotion
      • 5.2.3. Global Ivermectin by: End User (Value)
        • 5.2.3.1. Aged 18-65 Years
        • 5.2.3.2. Aged 0-17 Years
        • 5.2.3.3. Aged 65 and Above
      • 5.2.4. Global Ivermectin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Ivermectin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Perrigo Company plc (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Galderma Laboratories LP (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. MedinCell S.A (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Hebei Veyong Animal Pharmaceutical Co., Ltd., (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hovione Farmaciencia (Portugal)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Shandong Qilu King-Phar Pharmaceutical Co., Ltd. (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Zydus Cadila (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Ivermectin Sale, by Application, Form, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Ivermectin (Value)
      • 7.2.1. Global Ivermectin by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Research Centre
      • 7.2.2. Global Ivermectin by: Form (Value)
        • 7.2.2.1. Oral Tablet
        • 7.2.2.2. Cream
        • 7.2.2.3. Lotion
      • 7.2.3. Global Ivermectin by: End User (Value)
        • 7.2.3.1. Aged 18-65 Years
        • 7.2.3.2. Aged 0-17 Years
        • 7.2.3.3. Aged 65 and Above
      • 7.2.4. Global Ivermectin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ivermectin: by Application(USD Million)
  • Table 2. Ivermectin Hospitals , by Region USD Million (2014-2019)
  • Table 3. Ivermectin Clinics , by Region USD Million (2014-2019)
  • Table 4. Ivermectin Research Centre , by Region USD Million (2014-2019)
  • Table 5. Ivermectin: by Form(USD Million)
  • Table 6. Ivermectin Oral Tablet , by Region USD Million (2014-2019)
  • Table 7. Ivermectin Cream , by Region USD Million (2014-2019)
  • Table 8. Ivermectin Lotion , by Region USD Million (2014-2019)
  • Table 9. Ivermectin: by End User(USD Million)
  • Table 10. Ivermectin Aged 18-65 Years , by Region USD Million (2014-2019)
  • Table 11. Ivermectin Aged 0-17 Years , by Region USD Million (2014-2019)
  • Table 12. Ivermectin Aged 65 and Above , by Region USD Million (2014-2019)
  • Table 13. South America Ivermectin, by Country USD Million (2014-2019)
  • Table 14. South America Ivermectin, by Application USD Million (2014-2019)
  • Table 15. South America Ivermectin, by Form USD Million (2014-2019)
  • Table 16. South America Ivermectin, by End User USD Million (2014-2019)
  • Table 17. Brazil Ivermectin, by Application USD Million (2014-2019)
  • Table 18. Brazil Ivermectin, by Form USD Million (2014-2019)
  • Table 19. Brazil Ivermectin, by End User USD Million (2014-2019)
  • Table 20. Argentina Ivermectin, by Application USD Million (2014-2019)
  • Table 21. Argentina Ivermectin, by Form USD Million (2014-2019)
  • Table 22. Argentina Ivermectin, by End User USD Million (2014-2019)
  • Table 23. Rest of South America Ivermectin, by Application USD Million (2014-2019)
  • Table 24. Rest of South America Ivermectin, by Form USD Million (2014-2019)
  • Table 25. Rest of South America Ivermectin, by End User USD Million (2014-2019)
  • Table 26. Asia Pacific Ivermectin, by Country USD Million (2014-2019)
  • Table 27. Asia Pacific Ivermectin, by Application USD Million (2014-2019)
  • Table 28. Asia Pacific Ivermectin, by Form USD Million (2014-2019)
  • Table 29. Asia Pacific Ivermectin, by End User USD Million (2014-2019)
  • Table 30. China Ivermectin, by Application USD Million (2014-2019)
  • Table 31. China Ivermectin, by Form USD Million (2014-2019)
  • Table 32. China Ivermectin, by End User USD Million (2014-2019)
  • Table 33. Japan Ivermectin, by Application USD Million (2014-2019)
  • Table 34. Japan Ivermectin, by Form USD Million (2014-2019)
  • Table 35. Japan Ivermectin, by End User USD Million (2014-2019)
  • Table 36. India Ivermectin, by Application USD Million (2014-2019)
  • Table 37. India Ivermectin, by Form USD Million (2014-2019)
  • Table 38. India Ivermectin, by End User USD Million (2014-2019)
  • Table 39. South Korea Ivermectin, by Application USD Million (2014-2019)
  • Table 40. South Korea Ivermectin, by Form USD Million (2014-2019)
  • Table 41. South Korea Ivermectin, by End User USD Million (2014-2019)
  • Table 42. Taiwan Ivermectin, by Application USD Million (2014-2019)
  • Table 43. Taiwan Ivermectin, by Form USD Million (2014-2019)
  • Table 44. Taiwan Ivermectin, by End User USD Million (2014-2019)
  • Table 45. Australia Ivermectin, by Application USD Million (2014-2019)
  • Table 46. Australia Ivermectin, by Form USD Million (2014-2019)
  • Table 47. Australia Ivermectin, by End User USD Million (2014-2019)
  • Table 48. Rest of Asia-Pacific Ivermectin, by Application USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Ivermectin, by Form USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Ivermectin, by End User USD Million (2014-2019)
  • Table 51. Europe Ivermectin, by Country USD Million (2014-2019)
  • Table 52. Europe Ivermectin, by Application USD Million (2014-2019)
  • Table 53. Europe Ivermectin, by Form USD Million (2014-2019)
  • Table 54. Europe Ivermectin, by End User USD Million (2014-2019)
  • Table 55. Germany Ivermectin, by Application USD Million (2014-2019)
  • Table 56. Germany Ivermectin, by Form USD Million (2014-2019)
  • Table 57. Germany Ivermectin, by End User USD Million (2014-2019)
  • Table 58. France Ivermectin, by Application USD Million (2014-2019)
  • Table 59. France Ivermectin, by Form USD Million (2014-2019)
  • Table 60. France Ivermectin, by End User USD Million (2014-2019)
  • Table 61. Italy Ivermectin, by Application USD Million (2014-2019)
  • Table 62. Italy Ivermectin, by Form USD Million (2014-2019)
  • Table 63. Italy Ivermectin, by End User USD Million (2014-2019)
  • Table 64. United Kingdom Ivermectin, by Application USD Million (2014-2019)
  • Table 65. United Kingdom Ivermectin, by Form USD Million (2014-2019)
  • Table 66. United Kingdom Ivermectin, by End User USD Million (2014-2019)
  • Table 67. Netherlands Ivermectin, by Application USD Million (2014-2019)
  • Table 68. Netherlands Ivermectin, by Form USD Million (2014-2019)
  • Table 69. Netherlands Ivermectin, by End User USD Million (2014-2019)
  • Table 70. Rest of Europe Ivermectin, by Application USD Million (2014-2019)
  • Table 71. Rest of Europe Ivermectin, by Form USD Million (2014-2019)
  • Table 72. Rest of Europe Ivermectin, by End User USD Million (2014-2019)
  • Table 73. MEA Ivermectin, by Country USD Million (2014-2019)
  • Table 74. MEA Ivermectin, by Application USD Million (2014-2019)
  • Table 75. MEA Ivermectin, by Form USD Million (2014-2019)
  • Table 76. MEA Ivermectin, by End User USD Million (2014-2019)
  • Table 77. Middle East Ivermectin, by Application USD Million (2014-2019)
  • Table 78. Middle East Ivermectin, by Form USD Million (2014-2019)
  • Table 79. Middle East Ivermectin, by End User USD Million (2014-2019)
  • Table 80. Africa Ivermectin, by Application USD Million (2014-2019)
  • Table 81. Africa Ivermectin, by Form USD Million (2014-2019)
  • Table 82. Africa Ivermectin, by End User USD Million (2014-2019)
  • Table 83. North America Ivermectin, by Country USD Million (2014-2019)
  • Table 84. North America Ivermectin, by Application USD Million (2014-2019)
  • Table 85. North America Ivermectin, by Form USD Million (2014-2019)
  • Table 86. North America Ivermectin, by End User USD Million (2014-2019)
  • Table 87. United States Ivermectin, by Application USD Million (2014-2019)
  • Table 88. United States Ivermectin, by Form USD Million (2014-2019)
  • Table 89. United States Ivermectin, by End User USD Million (2014-2019)
  • Table 90. Canada Ivermectin, by Application USD Million (2014-2019)
  • Table 91. Canada Ivermectin, by Form USD Million (2014-2019)
  • Table 92. Canada Ivermectin, by End User USD Million (2014-2019)
  • Table 93. Mexico Ivermectin, by Application USD Million (2014-2019)
  • Table 94. Mexico Ivermectin, by Form USD Million (2014-2019)
  • Table 95. Mexico Ivermectin, by End User USD Million (2014-2019)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Ivermectin: by Application(USD Million)
  • Table 105. Ivermectin Hospitals , by Region USD Million (2020-2025)
  • Table 106. Ivermectin Clinics , by Region USD Million (2020-2025)
  • Table 107. Ivermectin Research Centre , by Region USD Million (2020-2025)
  • Table 108. Ivermectin: by Form(USD Million)
  • Table 109. Ivermectin Oral Tablet , by Region USD Million (2020-2025)
  • Table 110. Ivermectin Cream , by Region USD Million (2020-2025)
  • Table 111. Ivermectin Lotion , by Region USD Million (2020-2025)
  • Table 112. Ivermectin: by End User(USD Million)
  • Table 113. Ivermectin Aged 18-65 Years , by Region USD Million (2020-2025)
  • Table 114. Ivermectin Aged 0-17 Years , by Region USD Million (2020-2025)
  • Table 115. Ivermectin Aged 65 and Above , by Region USD Million (2020-2025)
  • Table 116. South America Ivermectin, by Country USD Million (2020-2025)
  • Table 117. South America Ivermectin, by Application USD Million (2020-2025)
  • Table 118. South America Ivermectin, by Form USD Million (2020-2025)
  • Table 119. South America Ivermectin, by End User USD Million (2020-2025)
  • Table 120. Brazil Ivermectin, by Application USD Million (2020-2025)
  • Table 121. Brazil Ivermectin, by Form USD Million (2020-2025)
  • Table 122. Brazil Ivermectin, by End User USD Million (2020-2025)
  • Table 123. Argentina Ivermectin, by Application USD Million (2020-2025)
  • Table 124. Argentina Ivermectin, by Form USD Million (2020-2025)
  • Table 125. Argentina Ivermectin, by End User USD Million (2020-2025)
  • Table 126. Rest of South America Ivermectin, by Application USD Million (2020-2025)
  • Table 127. Rest of South America Ivermectin, by Form USD Million (2020-2025)
  • Table 128. Rest of South America Ivermectin, by End User USD Million (2020-2025)
  • Table 129. Asia Pacific Ivermectin, by Country USD Million (2020-2025)
  • Table 130. Asia Pacific Ivermectin, by Application USD Million (2020-2025)
  • Table 131. Asia Pacific Ivermectin, by Form USD Million (2020-2025)
  • Table 132. Asia Pacific Ivermectin, by End User USD Million (2020-2025)
  • Table 133. China Ivermectin, by Application USD Million (2020-2025)
  • Table 134. China Ivermectin, by Form USD Million (2020-2025)
  • Table 135. China Ivermectin, by End User USD Million (2020-2025)
  • Table 136. Japan Ivermectin, by Application USD Million (2020-2025)
  • Table 137. Japan Ivermectin, by Form USD Million (2020-2025)
  • Table 138. Japan Ivermectin, by End User USD Million (2020-2025)
  • Table 139. India Ivermectin, by Application USD Million (2020-2025)
  • Table 140. India Ivermectin, by Form USD Million (2020-2025)
  • Table 141. India Ivermectin, by End User USD Million (2020-2025)
  • Table 142. South Korea Ivermectin, by Application USD Million (2020-2025)
  • Table 143. South Korea Ivermectin, by Form USD Million (2020-2025)
  • Table 144. South Korea Ivermectin, by End User USD Million (2020-2025)
  • Table 145. Taiwan Ivermectin, by Application USD Million (2020-2025)
  • Table 146. Taiwan Ivermectin, by Form USD Million (2020-2025)
  • Table 147. Taiwan Ivermectin, by End User USD Million (2020-2025)
  • Table 148. Australia Ivermectin, by Application USD Million (2020-2025)
  • Table 149. Australia Ivermectin, by Form USD Million (2020-2025)
  • Table 150. Australia Ivermectin, by End User USD Million (2020-2025)
  • Table 151. Rest of Asia-Pacific Ivermectin, by Application USD Million (2020-2025)
  • Table 152. Rest of Asia-Pacific Ivermectin, by Form USD Million (2020-2025)
  • Table 153. Rest of Asia-Pacific Ivermectin, by End User USD Million (2020-2025)
  • Table 154. Europe Ivermectin, by Country USD Million (2020-2025)
  • Table 155. Europe Ivermectin, by Application USD Million (2020-2025)
  • Table 156. Europe Ivermectin, by Form USD Million (2020-2025)
  • Table 157. Europe Ivermectin, by End User USD Million (2020-2025)
  • Table 158. Germany Ivermectin, by Application USD Million (2020-2025)
  • Table 159. Germany Ivermectin, by Form USD Million (2020-2025)
  • Table 160. Germany Ivermectin, by End User USD Million (2020-2025)
  • Table 161. France Ivermectin, by Application USD Million (2020-2025)
  • Table 162. France Ivermectin, by Form USD Million (2020-2025)
  • Table 163. France Ivermectin, by End User USD Million (2020-2025)
  • Table 164. Italy Ivermectin, by Application USD Million (2020-2025)
  • Table 165. Italy Ivermectin, by Form USD Million (2020-2025)
  • Table 166. Italy Ivermectin, by End User USD Million (2020-2025)
  • Table 167. United Kingdom Ivermectin, by Application USD Million (2020-2025)
  • Table 168. United Kingdom Ivermectin, by Form USD Million (2020-2025)
  • Table 169. United Kingdom Ivermectin, by End User USD Million (2020-2025)
  • Table 170. Netherlands Ivermectin, by Application USD Million (2020-2025)
  • Table 171. Netherlands Ivermectin, by Form USD Million (2020-2025)
  • Table 172. Netherlands Ivermectin, by End User USD Million (2020-2025)
  • Table 173. Rest of Europe Ivermectin, by Application USD Million (2020-2025)
  • Table 174. Rest of Europe Ivermectin, by Form USD Million (2020-2025)
  • Table 175. Rest of Europe Ivermectin, by End User USD Million (2020-2025)
  • Table 176. MEA Ivermectin, by Country USD Million (2020-2025)
  • Table 177. MEA Ivermectin, by Application USD Million (2020-2025)
  • Table 178. MEA Ivermectin, by Form USD Million (2020-2025)
  • Table 179. MEA Ivermectin, by End User USD Million (2020-2025)
  • Table 180. Middle East Ivermectin, by Application USD Million (2020-2025)
  • Table 181. Middle East Ivermectin, by Form USD Million (2020-2025)
  • Table 182. Middle East Ivermectin, by End User USD Million (2020-2025)
  • Table 183. Africa Ivermectin, by Application USD Million (2020-2025)
  • Table 184. Africa Ivermectin, by Form USD Million (2020-2025)
  • Table 185. Africa Ivermectin, by End User USD Million (2020-2025)
  • Table 186. North America Ivermectin, by Country USD Million (2020-2025)
  • Table 187. North America Ivermectin, by Application USD Million (2020-2025)
  • Table 188. North America Ivermectin, by Form USD Million (2020-2025)
  • Table 189. North America Ivermectin, by End User USD Million (2020-2025)
  • Table 190. United States Ivermectin, by Application USD Million (2020-2025)
  • Table 191. United States Ivermectin, by Form USD Million (2020-2025)
  • Table 192. United States Ivermectin, by End User USD Million (2020-2025)
  • Table 193. Canada Ivermectin, by Application USD Million (2020-2025)
  • Table 194. Canada Ivermectin, by Form USD Million (2020-2025)
  • Table 195. Canada Ivermectin, by End User USD Million (2020-2025)
  • Table 196. Mexico Ivermectin, by Application USD Million (2020-2025)
  • Table 197. Mexico Ivermectin, by Form USD Million (2020-2025)
  • Table 198. Mexico Ivermectin, by End User USD Million (2020-2025)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ivermectin: by Application USD Million (2014-2019)
  • Figure 5. Global Ivermectin: by Form USD Million (2014-2019)
  • Figure 6. Global Ivermectin: by End User USD Million (2014-2019)
  • Figure 7. South America Ivermectin Share (%), by Country
  • Figure 8. Asia Pacific Ivermectin Share (%), by Country
  • Figure 9. Europe Ivermectin Share (%), by Country
  • Figure 10. MEA Ivermectin Share (%), by Country
  • Figure 11. North America Ivermectin Share (%), by Country
  • Figure 12. Global Ivermectin share by Players 2019 (%)
  • Figure 13. Global Ivermectin share by Players (Top 3) 2019(%)
  • Figure 14. Global Ivermectin share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 18. Perrigo Company plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 19. Perrigo Company plc (Ireland) Revenue: by Geography 2019
  • Figure 20. Galderma Laboratories LP (United States) Revenue, Net Income and Gross profit
  • Figure 21. Galderma Laboratories LP (United States) Revenue: by Geography 2019
  • Figure 22. MedinCell S.A (France) Revenue, Net Income and Gross profit
  • Figure 23. MedinCell S.A (France) Revenue: by Geography 2019
  • Figure 24. Hebei Veyong Animal Pharmaceutical Co., Ltd., (China) Revenue, Net Income and Gross profit
  • Figure 25. Hebei Veyong Animal Pharmaceutical Co., Ltd., (China) Revenue: by Geography 2019
  • Figure 26. Hovione Farmaciencia (Portugal) Revenue, Net Income and Gross profit
  • Figure 27. Hovione Farmaciencia (Portugal) Revenue: by Geography 2019
  • Figure 28. Shandong Qilu King-Phar Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 29. Shandong Qilu King-Phar Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 30. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 31. Zydus Cadila (India) Revenue: by Geography 2019
  • Figure 32. Global Ivermectin: by Application USD Million (2020-2025)
  • Figure 33. Global Ivermectin: by Form USD Million (2020-2025)
  • Figure 34. Global Ivermectin: by End User USD Million (2020-2025)
  • Figure 35. South America Ivermectin Share (%), by Country
  • Figure 36. Asia Pacific Ivermectin Share (%), by Country
  • Figure 37. Europe Ivermectin Share (%), by Country
  • Figure 38. MEA Ivermectin Share (%), by Country
  • Figure 39. North America Ivermectin Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Merck & Co., Inc. (United States)
  • Perrigo Company plc (Ireland)
  • Galderma Laboratories LP (United States)
  • MedinCell S.A (France)
  • Hebei Veyong Animal Pharmaceutical Co., Ltd., (China)
  • Hovione Farmaciencia (Portugal)
  • Shandong Qilu King-Phar Pharmaceutical Co., Ltd. (China)
  • Zydus Cadila (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation